MiRScientific announces that the validation data for urine-based noninvasive prostate cancer testing are published in the Journal of Urology

Introduction: Adoption based on published data shows that it can have a significant impact, significantly improve patient outcomes, and reduce unnecessary interventions and waste.
validation data improves the ability to detect and characterize prostate cancer, sensitivity and specificity exceed 91% SentinelProstateTest ™ data integration to support patient treatment and decision-making Based on published data, the adoption of data shows that can have a very significant impact, significantly improve patient outcomes and reduce unnecessary interventions and waste, miRScientific, LLC announced on August 11th, its urine-based noninvasive cancer detection SentinelTest ™.
these data show that miRScientific's platform can detect molecular evidence of prostate cancer with a sensitivity of 94%, a specificity of 92% and a UC of 0.98. once
prostate cancer is diagnosed, the test will further classify the cancer as a low risk, with a sensitivity of 93%, a special degree of 90%, a UC 0.98, or a serious risk, sensitivity of 94%, speciality of 96%, AUC 0.99. The data released by the
highlight the results of tests based on urine exosomes, which are separated from a urine sample.
then interrogates hundreds of specific extracted non-coding small RNAs (sncRN) on a platform based on high-throughput real-time PCR and analyzes them using proprietary classification algorithms.
prostate cancer is the most common cancer, the second leading cause of cancer death for men in the United States, i is a major source of health inequality, and ii is a huge burden of disease on the shoulders of individuals, families, strained health systems and payers, including public institutions, private institutions and employers.
today, despite the dedication and ability of primary care physicians, urologists and oncologists, patients are primarily subjected to a 40-year-old PSA-based treatment that determines that a large number of men have elevated PSA and are at risk of prostate cancer, even though subsequent high lysopary tests have shown that they are not suffering from prostate cancer.
despite changes in the slicing, PSA testing often does not identify invasive diseases.
iiii is a fatal drawback because patients don't know they have cancer until they're in the late stages, so the risk of death and the cost of treatment is much higher. Sam Salman, chairman and chief executive of
, said: "MiRScientific is committed to providing methodological, clinically and scientifically proven techniques for all age-compliant men, particularly those with suspected cancer, to provide a particularly accurate, timely and actionable prostate cancer molecular condition through a urine sample.
our breakthrough platform allows us to reimagine how patients, doctors and other key healthcare stakeholders should: an independent test that covers communities of all ethnic and socioeconomic backgrounds, and data from the Journal of Urology shows that the results of overall improvement can be impacted by optimizing care, alleviating anxiety, eliminating avoidable conditions, and protecting lives and valuable financial and care resources.
" data included performance data from a case-control training and verification team of 1,436 subjects, including a retrospective sample of 613 patients from the GUBioBank University Health Network at Princess Margaret Hospital, and a review from Albany Medical Center, or "AMC." 823 subjects from the State University of New York's Lower State Medical Center ("DMC"), whose urine samples were collected from suspected prostate patients involved prior to the biopsy, were analyzed over a two-year period (2017-2019).
further described in the journal, the detection and validation groups were analyzed during the discovery phase using sncRNA sequences obtained from proprietary selection algorithms, comprising 235 participants from AMC and DMC. Dr. James McKiernan, professor of urology at
John K. Lattimer, chair of college-of-presbyterian and Surgeons urology, and chief urologist at New York-Presbyterian/Columbia, said: "The validation data published in the Journal of Urology ™ can significantly improve the most advanced innovation capabilities of doctors.
scientists, researchers, and biostatisticians involved in creating this ground-breaking platform are keeping a close eye on the needs of doctors, whose work has always revolved around early intervention to treat patients with invasive diseases, save lives, and improve the prognosis and quality of life of patients with painless diseases.
is proud to be part of a team of renowned physicians who will support the integration of miRScientific testing into clinical standards and practices.
" independent, scalable and non-invasive urine testing accurate final prostate cancer detection and classification has far-reaching potential implications.
a test that translates into better outcomes and better quality of life through traditional patient treatment and ongoing care.
from a male health perspective, empirical data in the Journal of Urology supports the continuing benefits to key stakeholders in large-scale adoption.
use data to meet age requirements, the early detection capability of miRScientificSentinel testing is expected to improve patient outcomes, which tends to minimize out-of-pocket costs. Similarly,
, because the journal's data include a representative population in large employer health plans, employees of all ethnicities and backgrounds can choose to benefit from the rapid, reliable, accurate and safe risk assessment and ongoing disease management of miRSentinel ScientificTest.
the high specificity and sensitivity of the data showed to support the avoidance of wasteful costs and lost working days, unnecessary surgery and treatment for patients can lead to wasteful costs and lost working days.
, as supported by the data, hospitals and clinics can benefit from the ability to safely prioritize the ability and medical talent to support patients with high-risk diseases, thanks to the ability of the miRScientificSentinelTest ™ people who have never had prostate or painless disease to identify high-risk patients.
, all types of payers may reduce claims for unnecessary surgery and related conditions, for example, by making active surveillance a more attractive option through non-invasive testing and reducing the cost of supporting interventions for advanced diseases.
Chairman and CEO Salman said that, based on the successful validation of its three independent Sentinel tests, miRScientific has now taken the final step of generating a fully integrated SentinelProstate test ™ through urine sample collection, which ultimately classifies subjects as one of four risks ("no molecular evidence of prostate cancer" (NMEPC), or one of patients with molecular evidence of prostate cancer - low risk, medium risk or high risk).
the company is preparing for a large-scale commercial launch of its Sentinel Prostate Test ™ as a test for CLIA and CLEP labs.
.